PortfoliosLab logo
NOV vs. NOVN.SW
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NOV and NOVN.SW is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

NOV vs. NOVN.SW - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in National Oilwell Varco, Inc. (NOV) and Novartis AG (NOVN.SW). The values are adjusted to include any dividend payments, if applicable.

200.00%400.00%600.00%800.00%1,000.00%1,200.00%NovemberDecember2025FebruaryMarchApril
228.27%
1,151.45%
NOV
NOVN.SW

Key characteristics

Sharpe Ratio

NOV:

-0.85

NOVN.SW:

0.48

Sortino Ratio

NOV:

-1.16

NOVN.SW:

0.72

Omega Ratio

NOV:

0.84

NOVN.SW:

1.11

Calmar Ratio

NOV:

-0.42

NOVN.SW:

0.56

Martin Ratio

NOV:

-1.55

NOVN.SW:

1.39

Ulcer Index

NOV:

22.82%

NOVN.SW:

6.81%

Daily Std Dev

NOV:

41.73%

NOVN.SW:

19.90%

Max Drawdown

NOV:

-89.77%

NOVN.SW:

-42.25%

Current Drawdown

NOV:

-83.94%

NOVN.SW:

-5.58%

Fundamentals

Market Cap

NOV:

$4.64B

NOVN.SW:

CHF 186.07B

EPS

NOV:

$1.60

NOVN.SW:

CHF 4.85

PE Ratio

NOV:

7.65

NOVN.SW:

19.42

PEG Ratio

NOV:

0.27

NOVN.SW:

1.31

PS Ratio

NOV:

0.52

NOVN.SW:

3.60

PB Ratio

NOV:

0.73

NOVN.SW:

5.07

Total Revenue (TTM)

NOV:

$6.72B

NOVN.SW:

CHF 39.60B

Gross Profit (TTM)

NOV:

$1.68B

NOVN.SW:

CHF 29.87B

EBITDA (TTM)

NOV:

$991.00M

NOVN.SW:

CHF 16.05B

Returns By Period

In the year-to-date period, NOV achieves a -17.37% return, which is significantly lower than NOVN.SW's 10.01% return. Over the past 10 years, NOV has underperformed NOVN.SW with an annualized return of -13.04%, while NOVN.SW has yielded a comparatively higher 5.76% annualized return.


NOV

YTD

-17.37%

1M

-19.95%

6M

-21.02%

1Y

-36.79%

5Y*

-0.09%

10Y*

-13.04%

NOVN.SW

YTD

10.01%

1M

-4.47%

6M

1.92%

1Y

9.80%

5Y*

8.09%

10Y*

5.76%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NOV vs. NOVN.SW — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NOV
The Risk-Adjusted Performance Rank of NOV is 1212
Overall Rank
The Sharpe Ratio Rank of NOV is 88
Sharpe Ratio Rank
The Sortino Ratio Rank of NOV is 1010
Sortino Ratio Rank
The Omega Ratio Rank of NOV is 1010
Omega Ratio Rank
The Calmar Ratio Rank of NOV is 2525
Calmar Ratio Rank
The Martin Ratio Rank of NOV is 66
Martin Ratio Rank

NOVN.SW
The Risk-Adjusted Performance Rank of NOVN.SW is 6767
Overall Rank
The Sharpe Ratio Rank of NOVN.SW is 7070
Sharpe Ratio Rank
The Sortino Ratio Rank of NOVN.SW is 5858
Sortino Ratio Rank
The Omega Ratio Rank of NOVN.SW is 6161
Omega Ratio Rank
The Calmar Ratio Rank of NOVN.SW is 7575
Calmar Ratio Rank
The Martin Ratio Rank of NOVN.SW is 6868
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NOV vs. NOVN.SW - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for National Oilwell Varco, Inc. (NOV) and Novartis AG (NOVN.SW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for NOV, currently valued at -0.86, compared to the broader market-2.00-1.000.001.002.003.00
NOV: -0.86
NOVN.SW: 0.90
The chart of Sortino ratio for NOV, currently valued at -1.18, compared to the broader market-6.00-4.00-2.000.002.004.00
NOV: -1.18
NOVN.SW: 1.27
The chart of Omega ratio for NOV, currently valued at 0.84, compared to the broader market0.501.001.502.00
NOV: 0.84
NOVN.SW: 1.20
The chart of Calmar ratio for NOV, currently valued at -0.42, compared to the broader market0.001.002.003.004.005.00
NOV: -0.42
NOVN.SW: 1.00
The chart of Martin ratio for NOV, currently valued at -1.54, compared to the broader market-5.000.005.0010.0015.0020.00
NOV: -1.54
NOVN.SW: 2.14

The current NOV Sharpe Ratio is -0.85, which is lower than the NOVN.SW Sharpe Ratio of 0.48. The chart below compares the historical Sharpe Ratios of NOV and NOVN.SW, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00NovemberDecember2025FebruaryMarchApril
-0.86
0.90
NOV
NOVN.SW

Dividends

NOV vs. NOVN.SW - Dividend Comparison

NOV's dividend yield for the trailing twelve months is around 2.50%, less than NOVN.SW's 3.72% yield.


TTM20242023202220212020201920182017201620152014
NOV
National Oilwell Varco, Inc.
2.50%1.88%0.99%0.96%0.37%0.36%0.80%0.78%0.56%1.63%5.49%2.46%
NOVN.SW
Novartis AG
3.72%3.72%3.77%3.91%3.94%3.72%3.27%3.98%3.98%4.35%3.58%3.17%

Drawdowns

NOV vs. NOVN.SW - Drawdown Comparison

The maximum NOV drawdown since its inception was -89.77%, which is greater than NOVN.SW's maximum drawdown of -42.25%. Use the drawdown chart below to compare losses from any high point for NOV and NOVN.SW. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-83.94%
-1.81%
NOV
NOVN.SW

Volatility

NOV vs. NOVN.SW - Volatility Comparison

National Oilwell Varco, Inc. (NOV) has a higher volatility of 26.69% compared to Novartis AG (NOVN.SW) at 14.98%. This indicates that NOV's price experiences larger fluctuations and is considered to be riskier than NOVN.SW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%NovemberDecember2025FebruaryMarchApril
26.69%
14.98%
NOV
NOVN.SW

Financials

NOV vs. NOVN.SW - Financials Comparison

This section allows you to compare key financial metrics between National Oilwell Varco, Inc. and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


2.00B4.00B6.00B8.00B10.00B12.00B14.00BAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
2.31B
13.56B
(NOV) Total Revenue
(NOVN.SW) Total Revenue
Please note, different currencies. NOV values in USD, NOVN.SW values in CHF

NOV vs. NOVN.SW - Profitability Comparison

The chart below illustrates the profitability comparison between National Oilwell Varco, Inc. and Novartis AG over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
21.4%
75.5%
(NOV) Gross Margin
(NOVN.SW) Gross Margin
NOV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2025, National Oilwell Varco, Inc. reported a gross profit of 493.00M and revenue of 2.31B. Therefore, the gross margin over that period was 21.4%.
NOVN.SW - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2025, Novartis AG reported a gross profit of 10.23B and revenue of 13.56B. Therefore, the gross margin over that period was 75.5%.
NOV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2025, National Oilwell Varco, Inc. reported an operating income of 207.00M and revenue of 2.31B, resulting in an operating margin of 9.0%.
NOVN.SW - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2025, Novartis AG reported an operating income of 3.53B and revenue of 13.56B, resulting in an operating margin of 26.0%.
NOV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2025, National Oilwell Varco, Inc. reported a net income of 160.00M and revenue of 2.31B, resulting in a net margin of 6.9%.
NOVN.SW - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2025, Novartis AG reported a net income of 2.82B and revenue of 13.56B, resulting in a net margin of 20.8%.